company background image
ZEGA logo

AstraZeneca DB:ZEGA Stock Report

Last Price

€61.00

Market Cap

€192.8b

7D

0%

1Y

-15.3%

Updated

25 May, 2025

Data

Company Financials +

ZEGA Stock Overview

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More details

ZEGA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance2/6
Financial Health3/6
Dividends4/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

AstraZeneca PLC Competitors

Price History & Performance

Summary of share price highs, lows and changes for AstraZeneca
Historical stock prices
Current Share PriceUK£61.00
52 Week HighUK£79.50
52 Week LowUK£57.50
Beta0.18
1 Month Change1.67%
3 Month Change-13.48%
1 Year Change-15.28%
3 Year Change-0.97%
5 Year Change24.49%
Change since IPO302.64%

Recent News & Updates

Recent updates

Shareholder Returns

ZEGADE PharmaceuticalsDE Market
7D0%2.0%-0.9%
1Y-15.3%-25.8%14.1%

Return vs Industry: ZEGA exceeded the German Pharmaceuticals industry which returned -25.8% over the past year.

Return vs Market: ZEGA underperformed the German Market which returned 14.1% over the past year.

Price Volatility

Is ZEGA's price volatile compared to industry and market?
ZEGA volatility
ZEGA Average Weekly Movement5.2%
Pharmaceuticals Industry Average Movement5.6%
Market Average Movement6.5%
10% most volatile stocks in DE Market12.7%
10% least volatile stocks in DE Market3.1%

Stable Share Price: ZEGA has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: ZEGA's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199294,300Pascal Claude Soriotwww.astrazeneca.com

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya.

AstraZeneca PLC Fundamentals Summary

How do AstraZeneca's earnings and revenue compare to its market cap?
ZEGA fundamental statistics
Market cap€192.81b
Earnings (TTM)€6.84b
Revenue (TTM)€48.40b
28.2x
P/E Ratio
4.0x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZEGA income statement (TTM)
RevenueUS$54.98b
Cost of RevenueUS$9.65b
Gross ProfitUS$45.33b
Other ExpensesUS$37.56b
EarningsUS$7.77b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Jul 29, 2025

Earnings per share (EPS)5.01
Gross Margin82.44%
Net Profit Margin14.14%
Debt/Equity Ratio73.3%

How did ZEGA perform over the long term?

See historical performance and comparison

Dividends

2.3%
Current Dividend Yield
62%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/25 01:43
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AstraZeneca PLC is covered by 82 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
John EadeArgus Research Company